View Clinical Trial (Medical Research Study)
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome
| City: |
|
Oklahoma City |
| State: |
|
Oklahoma |
| Zip Code: |
|
73104 |
| Conditions: |
|
Adult Respiratory Distress Syndrome - Acute Lung Injury |
| Purpose: |
|
Acute Lung Injury/Acute respiratory distress syndrome (ALI/ARDS) is a serious and frequently
encountered entity in modern ICUs. Sepsis remains the most common cause of ALI/ARDS and
carries the worst prognosis. The disease is characterized by an intense inflammatory
process. This inflammation plays a major role in the development of gas exchange
abnormalities seen in the course of the disease. Statins, primarily used as lipid-lowering
agents, are now known to possess anti-inflammatory, antioxidant, antithrombogenic and
vascular function-restoring actions. Therefore the investigators propose to determine if
Simvastatin may be useful in decreasing the incidence of this deadly syndrome in critically
ill patients.
|
| Study Summary: |
|
Patients will be enrolled within 24 hours of ICU admission and randomized to 1 of 2 groups:
Simvastatin or placebo. Patients' management will be entirely left up to the primary team,
including the need for daily laboratory and imaging. In addition, there will be no
restriction on the use of any medications, as deemed necessary by the primary care
physician. The primary endpoint will be the incidence of ALI/ARDS. Secondary efficacy
variables will be the number of days without organ or system failure, in addition to the
change in IL-6, IL-8, and TNF- α. Treatment will continue until the primary endpoint is
reached, the patient discharged from the ICU or the maximum duration of 2 weeks, whichever
occurs first. Patients will continued to be followed for a total of 28 days, or until
discharged from the hospital, whichever occurs first.
Patients randomized, in a ratio of 1:1 to either Simvastatin 40 mg PO once daily or placebo
tablet once daily in a format identical to Simvastatin.
The mortality from ALI/ARDS remains significant. In the absence of effective therapy,
prophylaxis in patients at risk is an important goal to achieve. Therefore, if Simvastatin
is found to decrease the incidence of ALI/ARDS, it would be a significant advance in the
management of this deadly and frequent syndrome.
We have set up a Data Safety Monitoring Board (DSMB) that will closely monitor the progress
of the trial (DSMB Charter attached to this application). Any adverse event will be reported
directly to the institutional review board (IRB) and DSMB. All adverse events will be
reported in the annual review of the protocol.
|
| Criteria: |
|
Inclusion Criteria:
- Adults older than 18 years of age, admitted to the ICU with one or more of the
following risk factors for ARDS/ALI:
- Sepsis, defined as the presence of infection-related systemic inflammatory
response syndrome (SIRS).
SIRS is defined as the presence of two or more of the following:
- Temperature >38.5ºC or <35ºC
- Heart rate >90 beats/min
- Respiratory rate >20 breaths/min or PaCO2 <32 mmHg
- WBC >12,000 cells/mm3, <4000 cells/mm3, or >10 percent immature (band) forms
- Pneumonia, including community and health care associated pneumonias
- Aspiration, defined as the witnessed inhalation of gastric contents
- Acute pancreatitis
- Bilateral lung contusion
- Massive transfusion, defined as more than 15 units of red blood cells/24h
- Multiple (>2) long-bone fractures
Exclusion Criteria:
- Patients already on a statin
- Current indication for statin therapy according to the National guidelines
- NPO order
- Active liver disease, defined as ALT or AST > 3 times the upper limits of normal
- History of myopathy
- History of uncontrolled seizure disorder
- Pregnancy or breastfeeding
- Immunosuppressive therapy, including prednisone at dose > 10 mg/day
- Preexistent lung disease indicated by history or chest film
- High risk for cardiogenic pulmonary edema (defined as the presence of ventricular
fibrillation, acute myocardial infarction, congestive heart failure with EF < 40%)
- High risk for neurogenic pulmonary edema (active CVA, or known increased intracranial
pressure)
|
| NCT ID: |
|
NCT01195428 |
| Primary Contact: |
|
Principal Investigator
Jean Keddissi, M.D.
University of Oklahoma
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Oklahoma City, Oklahoma 73104
United States
Jean I. Keddissi, MD
Phone: 405-271-6173
Email: jean-keddissi@ouhsc.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|